可疑甲状腺球蛋白增高性分化型甲状腺癌患者经131I治疗后的临床转归
China Oncology（2022）
Abstract
背景与目的:分化型甲状腺癌(differentiated?thyroid?cancer,DTC)中可疑甲状腺球蛋白(thyroglobulin,Tg)水平增高但无明确结构性病灶者预后差异大,临床治疗决策存在较大争议,本研究拟探究131I治疗及不同治疗剂量对于这类患者临床转归的影响.方法:回顾并分析2007—2021年就诊于北京协和医院核医学科的138例DTC全切术后可疑Tg水平增高的患者,依据首次131I治疗剂量分为低(剂量为1.11?GBq)、中(1.11?GBq<剂量≤3.70?GBq)、高(3.70?GBqMore
Translated text
Key words
|differentiated thyroid cancer|thyroglobulin|131i therapy|biochemical incomplete response
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined